Esanex
Indianapolis
About Esanex
Esanex is a drug development company focused on advancing its highly selective, orally active Hsp90 inhibitors. SNX-5422, created from a novel chemical scaffold that is unique in the Hsp90 field, has shown outstanding pre-clinical activity in a number of tumor models and is currently completing Phase 1 trials.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Total funding: $15.0M
- Last round: Series Unknown (Jun 2012)
Industries & Categories
Biotechnology, Developer Platform, Information Technology
Canonical: https://fsome.com/organization/esanex-258857 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.